SNAP-Flu - POP Biotechnologies
Alternative Names: Hexavalent seasonal influenza vaccine - POP Biotechnologies; SNAP-Flu nanoparticle vaccine - POP Biotechnologies; SNAPfluLatest Information Update: 30 Dec 2024
Price :
$50 *
At a glance
- Originator POP Biotechnologies
- Class Adjuvants; Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 30 Dec 2024 POP Biotechnologies has two patents for porphyrin-phospholipid (PoP) liposome technologies, namely the Spontaneous Nanoliposome Antigen Particleization (POP BIO SNAP) platform and Chemophototherapy (CPT) platform (POP Biotechnologies website, December 2024)
- 26 Nov 2024 POP Biotechnologies receives SBIR grant from National Institute of Allergies and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), for SNAP-Flu development in Influenza virus infection
- 26 Nov 2024 Preclinical trials in Influenza virus infections (Prevention) in USA (unspecified route) prior to December 2024